Carregant...
Tipus de document
Treball de fi de grauData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/223173
Phytotherapy as strategy to mitigate the toxicity of chemotherapy in breast cancer
Títol de la revista
Autors
ISSN de la revista
Títol del volum
Resum
This Final Degree Project explores the toxicity associated with chemotherapy in breast cancer, with particular focus on the molecular mechanisms behind adverse effects and the potential of pharmacogenetics and phytotherapy to mitigate them without compromising antitumor efficacy.
A comprehensive literature review was conducted to analyse the systemic toxicity of commonly used chemotherapeutic agents—such as anthracyclines, taxanes, cyclophosphamide, fluorouracil, platinum compounds, and cyclosporines—and the underlying
mechanisms, including oxidative stress, inflammation, and mitochondrial dysfunction.
The findings support the therapeutic potential of phytochemicals like Platycodon grandiflorum,
curcumin, kaempferol, and β-elemene to reduce chemotherapy-induced toxicity through antioxidant, anti-inflammatory, and pro-apoptotic actions. Furthermore, pharmacogenetic
markers in genes such as RARG, SLC28A3, and CYP2C8 show promise in predicting
individual susceptibility to adverse effects and in guiding personalised treatment.
The study concludes that integrating pharmacogenomics and phytotherapy into clinical oncology could enhance treatment adherence and patient quality of life. It emphasises the
need for translational research and clinical validation to support a more predictive, preventive, and personalised therapeutic model.
Keywords: breast cancer, chemotherapy toxicity, pharmacogenomics, phytotherapy, natural compounds.
Descripció
Treballs Finals de Grau de Farmàcia, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, 2025. Tutor/a: V. Ruiz de Porrás
Matèries (anglès)
Citació
Col·leccions
Citació
BENITO CABALLERO, Gisela. Phytotherapy as strategy to mitigate the toxicity of chemotherapy in breast cancer. [consulta: 28 de novembre de 2025]. [Disponible a: https://hdl.handle.net/2445/223173]